Gilead Sciences (GILD) Misses Q4 EPS by 83c; Offers 2022 Guidance

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $0.69, $0.83 worse than the analyst estimate of $1.52. Revenue for the quarter came in at $7.2 billion versus the consensus estimate of $6.51 billion.

GUIDANCE:

Gilead Sciences sees FY2022 EPS of $6.20-$6.70, versus the consensus of $6.91. Gilead Sciences sees FY2022 revenue of $23.8-24.3 billion, versus the consensus of $24.39 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
• BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18